Article
ABG Sundal Collier acted as Sole Financial Advisor in the SEK 40 million Pre-IPO of iCoat Medical
Transactions
iCoat Medical, the Swedish pharmaceutical company developing TUM012, a novel treatment in pre-clinical phase to minimize ischemia-related inflammation arising from kidney and other solid organ transplantations, has successfully completed a Pre-IPO capital raise of SEK 40 million. iCoat Medical will use the funding for clinical study phase 1 and other R&D.
Contact
